At 30 days, the rate of the primary end point—death or nonfatal reMI—was significantly lower in patients receiving enoxaparin than in patients receiving UFH (9.9% vs 12.0%, P < 0.001). The beneficial effect of enoxaparin was consistent across prespecified subgroups.

Antman EM, Morrow DA, McCabe CH, et al, for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarcton. N Engl J Med. 2006;354:1477-1488.